Justice Department, Drug Enforcement Administration Briefing 2026-05-20
Estimated reading time: 5 minutes
1. Revision of Applications for Manufacturing and Procurement Quotas
Sub: Justice Department, Drug Enforcement Administration
Content: The Drug Enforcement Administration (DEA) proposes to revise existing regulations relating to the management of quotas for schedule I and II controlled substances and the list I chemicals, ephedrine, pseudoephedrine, and phenylpropanolamine, to be utilized by DEA- registered manufacturers. This rule is being proposed to: restructure DEA's manufacturing and procurement quota regulations for more clarity and consistency; clarify which use-specific subcategories for quotas should be used for controlled substances that will be sold domestically and controlled substances that will be exported; and revise the applications for individual manufacturing and procurement quota. The changes are necessary to increase visibility into the controlled substance supply chain by providing DEA with more detailed information allowing the agency to react more precisely in preventing drug shortages; and to ensure that enough of the schedule I and II controlled substances and three list I chemicals can be manufactured to meet estimated scientific, medical, lawful export, and inventory needs. This rule also contains revisions to use gender neutral language and other non-substantive revisions.
2. Exempt Chemical Preparations Under the Controlled Substances Act
Sub: Justice Department, Drug Enforcement Administration
Content: The applications for exempt chemical preparations received by the Drug Enforcement Administration between July 1, 2025, and March 31, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through March 31, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published. This order also corrects the listing of several preparations that were published in the Federal Register notice on March 20, 2026.
3. Importer of Controlled Substances Application: Amneal Pharmaceuticals, LLC
Sub: Justice Department, Drug Enforcement Administration
Content: Amneal Pharmaceuticals, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
4. Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions LLC
Sub: Justice Department, Drug Enforcement Administration
Content: Organix Chemistry Solutions, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
5. Agency Information Collection Activities; Proposed Collection eComments Requested; Revision of a Previously Approved Collection; Title-Request To Be Included on the List of Pro Bono Legal Service Providers for Individuals in Immigration Proceedings (Form EOIR-56)
Sub: Justice Department
Content: The Executive Office for Immigration Review (EOIR), Department of Justice (DOJ), will be submitting the following information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
6. Agency Information Collection Activities; Proposed eCollection eComments Requested; New Collection: Title-Corporate Whistleblower Awards Pilot Program Online Intake Portal
Sub: Justice Department
Content: The Criminal Division, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
